News & Publications

News

Deals & Cases

CeQur SA raises USD 115 Million Series C5 Financing Round

12 April 2021 – CeQur SA a Swiss medical device company committed to simplifying the lives of people with diabetes by revolutionizing insulin-delivery solutions, announced the close of an oversubscribed $115 million equity financing.

The company will use the funds to advance commercial plans for CeQur Simplicity™, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing. CeQur Simplicity is both FDA cleared and CE-marked.

Credit Suisse Entrepreneur Capital Ltd and Endeavour Vision led the financing with significant participation from new investors, including Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Ypsomed Group (SWX: YPSN), Federated Hermes Kaufmann Funds, Kingdon Capital, and GMS Capital, as well as existing investors, Schroder & Co. Bank SA, and VI Partners.

Walder Wyss AG advised CeQur SA in the financing. The team was led by Patrick W. Vogel (Partner, Corporate/M&A) and included André Kuhn (Managing Associate, Corporate/M&A), Camille Tistounet (Trainee Lawyer) and Leandro Schafer (Trainee Lawyer).

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.